The diagnostic value of urinary transferrin compared to serum prostatic specific antigen (PSA) and prostatic acid phosphatase (PAP) in patients with prostatic cancer

Dieijen-Visser, Marja P. van; Hendriks, M.W.G.; Delaere, K.P.J.; Gijzen, A.H.J.; Brombacher, P. J.

doi:10.1016/0009-8981(88)90309-9

Cited by 10 publications

(5 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Five of these proteins (TYMP, ENDOD1, RFFL, CRYZL1 and ILF2) were detected with differential abundance when comparing to BPH group. In comparative studies using urine, the abundance levels of TF, ITIH4, AMPB, PTGDS, HP and UMOD were the same as in our study [ 23 , 26 , 29 , 38 ]. However, for ITIH4 and AMBP, there are also studies where opposite abundance levels were reported as well [ 31 , 38 ].…”

Section: Discussionmentioning

confidence: 80%

Proteomics analysis of urine reveals acute phase response proteins as candidate diagnostic biomarkers for prostate cancer

et al. 2015

View full text Add to dashboard Cite

Despite the overall success of prostate specific antigen (PSA) in screening and detection of prostate cancer (PCa), its use has been limited due to the lack of specificity. The principal driving goal currently within PCa research is to identify non-invasive biomarker(s) for early detection of aggressive tumors with greater sensitivity and specificity than PSA. In this study, we focused on identification of non-invasive biomarkers in urine with higher specificity than PSA. We tested urine samples from PCa and benign prostatic hyperplasia (BPH) patients by 2-D DIGE coupled with MS and bioinformatics analysis. Statistically significant (p < 0.05), 1.8 fold variation or more in abundance, showed 41 spots, corresponding to 23 proteins. The Ingenuity Pathway Analysis showed significant association with the Acute Phase Response Signaling pathway. Nine proteins with differential abundances were included in this pathway: AMBP, APOA1, FGA, FGG, HP, ITIH4, SERPINA1, TF and TTR. The expression pattern of 4 acute phase response proteins differed from the defined expression in the canonical pathway. The urine levels of TF, AMPB and HP were measured by immunoturbidimetry in an independent validation set. The concentration of AMPB in urine was significantly higher in PCa while levels of TF and HP were opposite (p < 0.05). The AUC for the individual proteins ranged from 0.723 to 0.754. The combination of HP and AMBP yielded the highest accuracy (AUC = 0.848), greater than PSA. The proposed biomarker set is quickly quantifiable and economical with potential to improve the sensitivity and specificity of PCa detection.Electronic supplementary materialThe online version of this article (doi:10.1186/s12953-014-0059-9) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 80%

Proteomics analysis of urine reveals acute phase response proteins as candidate diagnostic biomarkers for prostate cancer

et al. 2015

View full text Add to dashboard Cite

show abstract

“…The sensitivity and specificity for bladder tumor fibronectin were 43% and 77%, respectively (25 ), and for basic human arginine amidase were 47% and 100%, respectively (26 ). Two studies assessed scatter factor (27,28 ), 2 other studies assessed transferrin (or transferrin/creatinine ratio) (29,30 ), and 1 study assessed immunoglobulin concentrations (31 ) as potential biomarkers. All 5 studies reported rather poor performance characteristics as these potential markers showed either a sensitivity (27)(28)(29)31 ) or a specificity (30 ) near 30%.…”

Section: Resultsmentioning

confidence: 99%

“…All 5 studies reported rather poor performance characteristics as these potential markers showed either a sensitivity (27)(28)(29)31 ) or a specificity (30 ) near 30%. Furthermore, 3 of the studies (27,28,30 ) did not mention the ages of the participants, and 1 study (31 ) might have used a different sampling for cases and controls. In addition, the females used as controls by Rosen et al (28 ) could not be excluded from specificity calculations.…”

Section: Resultsmentioning

confidence: 99%

Urine Markers as Possible Tools for Prostate Cancer Screening: Review of Performance Characteristics and Practicality

Müller¹,

Brenner²

2006

Clinical Chemistry

View full text Add to dashboard Cite

Background:In recent years, an increasing number of urine-based tests have been proposed as potential screening tests for prostate cancer. The goal of this review was to summarize the current status of evidence regarding performance characteristics of the proposed tests and their practicality under screening conditions. Method: Relevant articles published up to and including May 2005 were identified in the PubMed database. At least 10 cases and 10 controls had to be analyzed for a study to be included in the review. Data concerning the study population, performance characteristics, and the collection and processing of urine samples were extracted from the reviewed articles. Results: In all, 34 retrospective studies evaluating 21 different markers complied with the inclusion criteria. Most of the studies were rather small and included heterogeneous clinical study populations. Promising results were reported for a few markers in single studies, but they have often not been replicated in subsequent larger studies. Some of the more promising results were obtained with 24-h urines or with specimenhandling procedures that might be difficult to perform under screening conditions. Conclusions: Larger studies with a prospective design are required to confirm promising findings regarding performance characteristics of some novel markers recently reported in mostly small studies. Future studies should also pay particular attention to the practicality of the markers under screening conditions.

show abstract

“…Transferrin levels were high in 18 of the 22 patients. By contrast, van Diejen et al [42] examined the diagnostic value of urinary transferrin in 34 men with cancer and 36 controls, finding a sensitivity of 75% and specificity of 30%. They concluded that serum PSA and prostate acid phosphatase level had better diagnostic value.…”

Section: Protein Markersmentioning

confidence: 99%

Urinary markers for prostate cancer

et al. 2006

View full text Add to dashboard Cite

Prostate cancer is the commonest solid‐organ malignancy to affect men in Europe and the USA; it is estimated that one in six men will develop this cancer in their lifetime. Current screening relies on a digital rectal examination with a serum prostate‐specific antigen test. Novel urinary diagnostic tests are potentially interesting screening tools for this disease. We examined published reports assessing the use of urinary markers for the diagnosis of prostate cancer. Using a PubMed‐based search we identified studies of urinary markers for prostate cancer published from 1985 to February 2006 using the search terms ‘urine’, ‘marker’ and ‘prostate cancer’. Studies to date have used small cohorts and relied on prostatic biopsies to provide histology. The sensitivity and specificity of markers are wide ranging but with only a few studies published on each putative marker it is difficult to assess their potential impact. Using urinary biomarkers for prostate cancer is a relatively novel diagnostic approach; they are appealing as a screening test because they are not invasive. Further work is needed to identify and validate ‘signature markers’ indicative of prostatic malignancy. The newer proteomic platforms are promising biomarker discovery tools that might uncover the next generation of urinary biomarkers.

show abstract

The diagnostic value of urinary transferrin compared to serum prostatic specific antigen (PSA) and prostatic acid phosphatase (PAP) in patients with prostatic cancer

Cited by 10 publications

References 3 publications

Proteomics analysis of urine reveals acute phase response proteins as candidate diagnostic biomarkers for prostate cancer

Proteomics analysis of urine reveals acute phase response proteins as candidate diagnostic biomarkers for prostate cancer

Urine Markers as Possible Tools for Prostate Cancer Screening: Review of Performance Characteristics and Practicality

Urinary markers for prostate cancer

Contact Info

Product

Resources

About